These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31995025)

  • 1. Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues.
    Cozzi R; Ambrosio MR; Attanasio R; Bozzao A; De Marinis L; De Menis E; Guastamacchia E; Lania A; Lasio G; Logoluso F; Maffei P; Poggi M; Toscano V; Zini M; Chanson P; Katznelson L
    Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1144-1155. PubMed ID: 31995025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues.
    Cozzi R; Ambrosio MR; Attanasio R; Bozzao A; De Marinis L; De Menis E; Guastamacchia E; Lania A; Lasio G; Logoluso F; Maffei P; Poggi M; Toscano V; Zini M; Chanson P; Katznelson L
    Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1133-1143. PubMed ID: 31985386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
    Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
    Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
    Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical-pharmacological interactions in the treatment of acromegaly.
    Abreu C; Guinto G; Mercado M
    Expert Rev Endocrinol Metab; 2019 Jan; 14(1):35-42. PubMed ID: 30595057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
    Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
    Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
    Chiloiro S; Giampietro A; Mirra F; Donfrancesco F; Tartaglione T; Mattogno PP; Angelini F; Liverana L; Gessi M; Carmelo A; Rindi G; Giustina A; Fleseriu M; Pontecorvi A; De Marinis L; Bianchi A
    Eur J Endocrinol; 2021 Feb; 184(2):217-229. PubMed ID: 33136550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
    Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
    Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology.
    Bolanowski M; Ruchała M; Zgliczyński W; Kos-Kudła B; Hubalewska-Dydejczyk A; Lewiński A
    Endokrynol Pol; 2019; 70(1):2-18. PubMed ID: 30843181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pasireotide: a novel treatment for patients with acromegaly.
    Cuevas-Ramos D; Fleseriu M
    Drug Des Devel Ther; 2016; 10():227-39. PubMed ID: 26811671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
    Ciresi A; Radellini S; Guarnotta V; Giordano C
    BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
    Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
    J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational therapies for acromegaly.
    Grasso LF; Pivonello R; Colao A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):955-63. PubMed ID: 23731031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.
    Bianchi A; Valentini F; Iuorio R; Poggi M; Baldelli R; Passeri M; Giampietro A; Tartaglione L; Chiloiro S; Appetecchia M; Gargiulo P; Fabbri A; Toscano V; Pontecorvi A; De Marinis L
    J Exp Clin Cancer Res; 2013 Jun; 32(1):40. PubMed ID: 23799893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second line treatment of acromegaly: Pasireotide or Pegvisomant?
    Chiloiro S; Bianchi A; Giampietro A; Pontecorvi A; Raverot G; Marinis L
    Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101684. PubMed ID: 35931640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?
    Grasso LF; Pivonello R; Colao A
    Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):288-94. PubMed ID: 22627686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: MANAGEMENT OF ACROMEGALY PATIENTS: WHAT IS THE ROLE OF PRE-OPERATIVE MEDICAL THERAPY?
    Fleseriu M; Hoffman AR; Katznelson L;
    Endocr Pract; 2015 Jun; 21(6):668-73. PubMed ID: 26135961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study.
    Bogazzi F; Colao A; Rossi G; Lombardi M; Urbani C; Sardella C; Iannelli A; Scattina I; Manetti L; Del Sarto S; Pivonello R; Grasso LF; Lupi I; Auriemma RS; Lombardi G; Martino E
    Eur J Endocrinol; 2013 Sep; 169(3):367-76. PubMed ID: 23828855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.